Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. SPY
6. ACN
7. NVDA
8. IBM
9. PFE
10. TSLA

Go back to Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
(NASDAQ: OCGN) Delayed: 1.42 +0.13 (10.08%)
Previous Close $1.29    52 Week High $ 
Open $1.28    52 Week Low $ 
Day High $1.43    P/E N/A 
Day Low $1.28    EPS $ 
Volume 6,176,869